{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:29:32Z","timestamp":1787315372588,"version":"build-2736575974"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Patients with Nagashima-type palmoplantar keratoderma (NPPK) experience progressive, painful hyperkeratosis and fissuring of palms and soles that limits daily activities Due to the incomplete understanding of its pathogenesis, there are currently no effective treatments for NPPK. We report a 26-year-old woman with lifelong, worsening palmoplantar keratoderma, nail dystrophy, and concomitant atopic dermatitis refractory to topical treatments. Next-generation sequencing revealed compound heterozygous mutations in\n                    <jats:italic>SERPINB7<\/jats:italic>\n                    (c.796C&amp;gt;T, p.Arg266Ter) and\n                    <jats:italic>filaggrin<\/jats:italic>\n                    (FLG, c.3321delA, p.Gly1109GlufsTer13), while her asymptomatic parents and brother carried only single heterozygous variants, underscoring the digenic pathogenesis in our patient. After 42 weeks of dupilumab treatment, palmoplantar keratosis and nail changes had almost completely resolved, and the eruption resembled mild chronic eczema. Dupilumab therefore appears to be a safe and effective option for digenic NPPK complicated by atopic dermatitis and warrants further investigation in larger cohorts.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1647441","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:29:48Z","timestamp":1758778188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Dupilumab treatment for Chinese Nagashima-type palmoplantar keratoderma associated with atopic dermatitis: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Chunting","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13076","article-title":"Highly prevalent SERPINB7 founder mutation causes pseudodominant inheritance pattern in Nagashima-type palmoplantar keratosis","volume":"171","author":"Mizuno","year":"2014","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.156","article-title":"Nagashima-type palmoplantar keratosis: a common Asian type caused by SERPINB7 protease inhibitor deficiency","volume":"134","author":"Kubo","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16621","article-title":"Investigation of Nagashima-type palmoplantar keratoderma in China: A cross-sectional study of 234 patients","volume":"50","author":"Liu","year":"2023","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09582.x","article-title":"FLG mutations in ichthyosis vulgaris and atopic eczema: spectrum of mutations and population genetics","volume":"162","author":"Akiyama","year":"2010","journal-title":"Br J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.jaci.2021.07.043","article-title":"Uniting biobank resources reveals novel genetic pathways modulating susceptibility for atopic dermatitis","volume":"149","author":"Sliz","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjd.19144","article-title":"Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature","volume":"184","author":"Bodemer","year":"2021","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12389","article-title":"Application of topical gentamicin ointment in the treatment of Nagashima-type palmoplantar keratosis in children with a nonsense mutation","volume":"7","author":"Wang","year":"2023","journal-title":"Pediatr Investig"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2013.09.015","article-title":"Mutations in SERPINB7, encoding a member of the serine protease inhibitor superfamily, cause Nagashima-type palmoplantar keratosis","volume":"93","author":"Kubo","year":"2013","journal-title":"Am J Hum Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.004","article-title":"Nagashima-type palmoplantar keratosis in Finland caused by a SERPINB7 founder mutation","volume":"83","author":"Hannula-Jouppi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15265","article-title":"Nagashima-type palmoplantar keratoderma: Case series and two novel variants","volume":"40","author":"Braun","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/mmr.2024.13235","article-title":"Genetic analysis of seven patients with inherited ichthyosis and Nagashima\u2212type palmoplantar keratoderma","volume":"30","author":"Zhang","year":"2024","journal-title":"Mol Med Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4608","article-title":"Treatment of netherton syndrome with dupilumab","volume":"156","author":"Steuer","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18350","article-title":"Dupilumab in Hailey-Hailey disease: a case series","volume":"36","author":"Alamon-Reig","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20475","article-title":"Hailey-Hailey disease treated with dupilumab: a case series","volume":"185","author":"Alzahrani","year":"2021","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"adv41984","DOI":"10.2340\/actadv.v104.41984","article-title":"Clinical improvement of bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma in two patients treated with dupilumab","volume":"104","author":"Pascolini","year":"2024","journal-title":"Acta Derm Venereol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1647441\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:29:48Z","timestamp":1758778188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1647441\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2025.1647441"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1647441","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1647441"}}